减少ANCA相关血管炎利妥昔单抗维持治疗初始输注次数的随机试验事后分析
该研究为MAINRITSAN2随机对照试验的事后分析,评估省略第14天利妥昔单抗输注对ANCA相关血管炎12个月时无复发生存率的影响。结果显示,D0组与D0+D14组在M3、M6、M9、M12的无复发生存率均无组间差异,且不受诱导方案或疾病状态影响。提示省略D14维持剂量可能不改变短期无复发率,但M12结果也可能受两组输注策略影响。
要点
- MAINRITSAN2事后分析比较D0与D0+D14利妥昔单抗方案,12个月内无复发生存率无差异。
- M12时D0组无复发73/80(91.3%),D0+D14组76/81(93.8%)。
- 结果不受环磷酰胺或利妥昔单抗诱导、新诊断或复发状态影响。
核心结论
- 未检测到D0与D0+D14利妥昔单抗输注组至M12无复发生存率的差异,提示省略D14维持剂量可能不改变短期无复发率。
研究设计与样本
- MAINRITSAN2随机对照试验的事后分析,纳入161例患者,比较D0组(80例)与D0+D14组(81例)。
主要发现
- M3、M6、M9、M12时,D0组无复发生存分别为79/80(98.8%)、76/80(95%)、74/80(92.5%)、73/80(91.3%)。
- M3、M6、M9、M12时,D0+D14组无复发生存分别为80/81(98.8%)、78/81(96.3%)、76/81(93.8%)、76/81(93.8%)。
- 组间无差异,且不受环磷酰胺或利妥昔单抗诱导、新诊断或复发AAV影响。
关键数值与推荐
- D0组与D0+D14组在M12的无复发生存率分别为91.3%和93.8%,组间无差异。
临床怎么用
- 对于接受利妥昔单抗维持治疗的ANCA相关血管炎患者,省略D14输注可能不影响12个月内无复发率。
局限性
- M12结果可能也受两组利妥昔单抗输注策略影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter's titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12. METHODS: MAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free survival rates in each arm as primary end points. Exploratory subgroup analyses were run according to CYC or rituximab induction and newly diagnosed or relapsing AAV. RESULTS: At M3, M6, M9 and M12, respectively, among the 161 patients included, 79/80 (98.8%), 76/80 (95%), 74/80 (92.5%) and 73/80 (91.3%) from D0, and 80/81 (98.8%), 78/81 (96.3%), 76/81 (93.8%) and 76/81 (93.8%) from D0+D14 groups were alive and relapse-free. No between-group differences were observed. Results were not affected by CYC or rituximab induction, or newly diagnosed or relapsing AAV. CONCLUSIONS: We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse-free rate. Nevertheless, results at M12 may also have been influenced by the rituximab-infusion strategies for both groups.
引用
- Charles P, Dechartres A, Terrier B, et al. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). 2020. PMID: 32150263. doi:10.1093/rheumatology/kez621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。